A strategy for the development of two clinically active cisplatin analogs : CBDCA and CHIP
The antitumor agent cisplatin has a broad antitumor spectrum and has been incorporated into regimens that are curative for some malignant diseases. However, one of the major limitations to its clinical usefulness is the incidence of severe toxicities involving several major organ systems. Therefore,...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 1990, Vol.25 (6), p.395-404 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 404 |
|---|---|
| container_issue | 6 |
| container_start_page | 395 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 25 |
| creator | FOSTER, B. J HARDIN, B. J WOLPERT-DEFILIPPES, M. K RUBINSTEIN, L. Y CLAGETT-CARR, K LEYLAND-JONES, B |
| description | The antitumor agent cisplatin has a broad antitumor spectrum and has been incorporated into regimens that are curative for some malignant diseases. However, one of the major limitations to its clinical usefulness is the incidence of severe toxicities involving several major organ systems. Therefore, much enthusiasm has been generated for the development of cisplatin analogs that demonstrate an improved therapeutic index in some preclinical models. The two most promising analogs are CBDCA (carboplatin) and CHIP (iproplatin). The preclinical and early clinical trial results have demonstrated that these two compounds show activity in cisplatin-responsive tumors. The preclinical background providing the rationale for the clinical development of these two analogs is described. We suggest a means of screening for each analog's clinical antitumor activity and determining the analogs' utility against specific malignant diseases compared with that of the parent compound or standard treatment. |
| doi_str_mv | 10.1007/bf00686049 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00686049</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2178792</sourcerecordid><originalsourceid>FETCH-LOGICAL-c293t-cfd40e83eb293305467e158a052f027567a070f5d1e9ccbb2e181e4871c462193</originalsourceid><addsrcrecordid>eNpFkE1Lw0AYhBdRaq1evAt78SJE3_3KJt7aaG2hoAe9eAmbzbs1kiYhu1b6741Y9TQM8zAwQ8g5g2sGoG8KBxAnMcj0gIyZFDyCRIpDMgYhZaQ0yGNy4v07AEgmxIiMONOJTvmYvE6pD70JuN5R1_Y0vCEtcYt1222wCbR1NHy21NZVU1lT1ztqbKi2SG3lu9qEqqGmMXW79vSWZrO7bDr4kmaL5dMpOXKm9ni21wl5md8_Z4to9fiwzKaryPJUhMi6UgImAovBClAy1shUYkBxB1yrWBvQ4FTJMLW2KDiyhKFMNLMy5iwVE3L102v71vseXd711cb0u5xB_v1PPpv__jPAFz9w91FssPxD94cM-eU-N37Y63rTDEv_G1OdqpjH4gsKBmrN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A strategy for the development of two clinically active cisplatin analogs : CBDCA and CHIP</title><source>MEDLINE</source><source>SpringerLink</source><creator>FOSTER, B. J ; HARDIN, B. J ; WOLPERT-DEFILIPPES, M. K ; RUBINSTEIN, L. Y ; CLAGETT-CARR, K ; LEYLAND-JONES, B</creator><creatorcontrib>FOSTER, B. J ; HARDIN, B. J ; WOLPERT-DEFILIPPES, M. K ; RUBINSTEIN, L. Y ; CLAGETT-CARR, K ; LEYLAND-JONES, B</creatorcontrib><description>The antitumor agent cisplatin has a broad antitumor spectrum and has been incorporated into regimens that are curative for some malignant diseases. However, one of the major limitations to its clinical usefulness is the incidence of severe toxicities involving several major organ systems. Therefore, much enthusiasm has been generated for the development of cisplatin analogs that demonstrate an improved therapeutic index in some preclinical models. The two most promising analogs are CBDCA (carboplatin) and CHIP (iproplatin). The preclinical and early clinical trial results have demonstrated that these two compounds show activity in cisplatin-responsive tumors. The preclinical background providing the rationale for the clinical development of these two analogs is described. We suggest a means of screening for each analog's clinical antitumor activity and determining the analogs' utility against specific malignant diseases compared with that of the parent compound or standard treatment.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/bf00686049</identifier><identifier>PMID: 2178792</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Animals ; Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Biological and medical sciences ; Carboplatin ; Chemical Phenomena ; Chemistry ; Chemotherapy ; Cisplatin - analogs & derivatives ; Drug Design ; Drug Evaluation ; Drug Screening Assays, Antitumor ; Humans ; Leukemia L1210 - drug therapy ; Male ; Medical sciences ; Mice ; Neoplasms, Experimental - drug therapy ; Organoplatinum Compounds - adverse effects ; Organoplatinum Compounds - pharmacology ; Organoplatinum Compounds - therapeutic use ; Pharmacology. Drug treatments ; Rats ; Rats, Inbred F344</subject><ispartof>Cancer chemotherapy and pharmacology, 1990, Vol.25 (6), p.395-404</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c293t-cfd40e83eb293305467e158a052f027567a070f5d1e9ccbb2e181e4871c462193</citedby><cites>FETCH-LOGICAL-c293t-cfd40e83eb293305467e158a052f027567a070f5d1e9ccbb2e181e4871c462193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4009,27902,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19795626$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2178792$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FOSTER, B. J</creatorcontrib><creatorcontrib>HARDIN, B. J</creatorcontrib><creatorcontrib>WOLPERT-DEFILIPPES, M. K</creatorcontrib><creatorcontrib>RUBINSTEIN, L. Y</creatorcontrib><creatorcontrib>CLAGETT-CARR, K</creatorcontrib><creatorcontrib>LEYLAND-JONES, B</creatorcontrib><title>A strategy for the development of two clinically active cisplatin analogs : CBDCA and CHIP</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>The antitumor agent cisplatin has a broad antitumor spectrum and has been incorporated into regimens that are curative for some malignant diseases. However, one of the major limitations to its clinical usefulness is the incidence of severe toxicities involving several major organ systems. Therefore, much enthusiasm has been generated for the development of cisplatin analogs that demonstrate an improved therapeutic index in some preclinical models. The two most promising analogs are CBDCA (carboplatin) and CHIP (iproplatin). The preclinical and early clinical trial results have demonstrated that these two compounds show activity in cisplatin-responsive tumors. The preclinical background providing the rationale for the clinical development of these two analogs is described. We suggest a means of screening for each analog's clinical antitumor activity and determining the analogs' utility against specific malignant diseases compared with that of the parent compound or standard treatment.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Carboplatin</subject><subject>Chemical Phenomena</subject><subject>Chemistry</subject><subject>Chemotherapy</subject><subject>Cisplatin - analogs & derivatives</subject><subject>Drug Design</subject><subject>Drug Evaluation</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Humans</subject><subject>Leukemia L1210 - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Neoplasms, Experimental - drug therapy</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Organoplatinum Compounds - pharmacology</subject><subject>Organoplatinum Compounds - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Rats, Inbred F344</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1Lw0AYhBdRaq1evAt78SJE3_3KJt7aaG2hoAe9eAmbzbs1kiYhu1b6741Y9TQM8zAwQ8g5g2sGoG8KBxAnMcj0gIyZFDyCRIpDMgYhZaQ0yGNy4v07AEgmxIiMONOJTvmYvE6pD70JuN5R1_Y0vCEtcYt1222wCbR1NHy21NZVU1lT1ztqbKi2SG3lu9qEqqGmMXW79vSWZrO7bDr4kmaL5dMpOXKm9ni21wl5md8_Z4to9fiwzKaryPJUhMi6UgImAovBClAy1shUYkBxB1yrWBvQ4FTJMLW2KDiyhKFMNLMy5iwVE3L102v71vseXd711cb0u5xB_v1PPpv__jPAFz9w91FssPxD94cM-eU-N37Y63rTDEv_G1OdqpjH4gsKBmrN</recordid><startdate>1990</startdate><enddate>1990</enddate><creator>FOSTER, B. J</creator><creator>HARDIN, B. J</creator><creator>WOLPERT-DEFILIPPES, M. K</creator><creator>RUBINSTEIN, L. Y</creator><creator>CLAGETT-CARR, K</creator><creator>LEYLAND-JONES, B</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1990</creationdate><title>A strategy for the development of two clinically active cisplatin analogs : CBDCA and CHIP</title><author>FOSTER, B. J ; HARDIN, B. J ; WOLPERT-DEFILIPPES, M. K ; RUBINSTEIN, L. Y ; CLAGETT-CARR, K ; LEYLAND-JONES, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c293t-cfd40e83eb293305467e158a052f027567a070f5d1e9ccbb2e181e4871c462193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Carboplatin</topic><topic>Chemical Phenomena</topic><topic>Chemistry</topic><topic>Chemotherapy</topic><topic>Cisplatin - analogs & derivatives</topic><topic>Drug Design</topic><topic>Drug Evaluation</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Humans</topic><topic>Leukemia L1210 - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Neoplasms, Experimental - drug therapy</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Organoplatinum Compounds - pharmacology</topic><topic>Organoplatinum Compounds - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Rats, Inbred F344</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FOSTER, B. J</creatorcontrib><creatorcontrib>HARDIN, B. J</creatorcontrib><creatorcontrib>WOLPERT-DEFILIPPES, M. K</creatorcontrib><creatorcontrib>RUBINSTEIN, L. Y</creatorcontrib><creatorcontrib>CLAGETT-CARR, K</creatorcontrib><creatorcontrib>LEYLAND-JONES, B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FOSTER, B. J</au><au>HARDIN, B. J</au><au>WOLPERT-DEFILIPPES, M. K</au><au>RUBINSTEIN, L. Y</au><au>CLAGETT-CARR, K</au><au>LEYLAND-JONES, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A strategy for the development of two clinically active cisplatin analogs : CBDCA and CHIP</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1990</date><risdate>1990</risdate><volume>25</volume><issue>6</issue><spage>395</spage><epage>404</epage><pages>395-404</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>The antitumor agent cisplatin has a broad antitumor spectrum and has been incorporated into regimens that are curative for some malignant diseases. However, one of the major limitations to its clinical usefulness is the incidence of severe toxicities involving several major organ systems. Therefore, much enthusiasm has been generated for the development of cisplatin analogs that demonstrate an improved therapeutic index in some preclinical models. The two most promising analogs are CBDCA (carboplatin) and CHIP (iproplatin). The preclinical and early clinical trial results have demonstrated that these two compounds show activity in cisplatin-responsive tumors. The preclinical background providing the rationale for the clinical development of these two analogs is described. We suggest a means of screening for each analog's clinical antitumor activity and determining the analogs' utility against specific malignant diseases compared with that of the parent compound or standard treatment.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>2178792</pmid><doi>10.1007/bf00686049</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 1990, Vol.25 (6), p.395-404 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00686049 |
| source | MEDLINE; SpringerLink |
| subjects | Animals Antineoplastic agents Antineoplastic Agents - pharmacology Biological and medical sciences Carboplatin Chemical Phenomena Chemistry Chemotherapy Cisplatin - analogs & derivatives Drug Design Drug Evaluation Drug Screening Assays, Antitumor Humans Leukemia L1210 - drug therapy Male Medical sciences Mice Neoplasms, Experimental - drug therapy Organoplatinum Compounds - adverse effects Organoplatinum Compounds - pharmacology Organoplatinum Compounds - therapeutic use Pharmacology. Drug treatments Rats Rats, Inbred F344 |
| title | A strategy for the development of two clinically active cisplatin analogs : CBDCA and CHIP |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T17%3A42%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20strategy%20for%20the%20development%20of%20two%20clinically%20active%20cisplatin%20analogs%20:%20CBDCA%20and%20CHIP&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=FOSTER,%20B.%20J&rft.date=1990&rft.volume=25&rft.issue=6&rft.spage=395&rft.epage=404&rft.pages=395-404&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/bf00686049&rft_dat=%3Cpubmed_cross%3E2178792%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2178792&rfr_iscdi=true |